Literature DB >> 10768092

Glycation impairs high-density lipoprotein function.

C C Hedrick1, S R Thorpe, M X Fu, C M Harper, J Yoo, S M Kim, H Wong, A L Peters.   

Abstract

AIMS/HYPOTHESIS: To examine the effects of incubation of high-density lipoprotein (HDL) under hyperglycaemic conditions on several functions of HDL in vitro.
METHODS: Human HDL (5 mg protein) was incubated for 1 week at 37 degrees C in the presence or absence of 25 mmol/l glucose. Additional samples of human HDL were incubated in butylated hydroxytoluene to control for oxidation.
RESULTS: High-density lipoprotein incubated for 1 week in 25 mmol/l glucose had significant increases in the glycation product, fructoselysine and in the advanced glycation end product, N epsilon-(carboxymethyl)-lysine. High-density lipoprotein apolipoprotein AI and AII concentrations were not altered but glycated HDL had a 65% reduction in paraoxonase enzymatic activity. Glycated HDL did not inhibit monocyte adhesion to human aortic endothelial cells in response to oxidised low-density lipoprotein in vitro (43 +/- 4 monocytes bound vs 21 +/- 2 monocytes for control HDL, p < 0.0001). Hepatic lipase-mediated non-esterified fatty acid release from HDL lipids was enhanced in glycated HDL compared with control HDL (25 +/- 1 vs 16 +/- 1 nmol non-esterified fatty acid hydrolysed/min, respectively, p < 0.0001). Direct glycation of purified paraoxonase protein by incubation in 25 mmol/l glucose caused a 40% reduction in enzymatic activity. This glycated paraoxonase did not inhibit monocyte adhesion to human aortic endothelial cells in vitro (68 +/- 3 monocytes vs 49 +/- 2 monocytes bound for control paraoxonase, respectively, p < 0.001). We also measured a 40% reduction in paraoxonase activity in patients with Type II (non-insulin-dependent) diabetes mellitus and documented coronary artery disease compared with non-diabetic subjects, p < 0.0001. CONCLUSIONS/
INTERPRETATION: Alterations in function of HDL caused by exposure to hyperglycaemic conditions could contribute to the accelerated atherosclerosis observed in Type II diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768092     DOI: 10.1007/s001250050049

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  59 in total

1.  Paraoxonase 1 activity in chylomicrons and VLDL: the effect of type 2 diabetes and meals rich in saturated fat and oleic acid.

Authors:  Patrick J Manning; Sylvia A de Jong; Anne R Ryalls; Wayne H F Sutherland
Journal:  Lipids       Date:  2011-12-10       Impact factor: 1.880

Review 2.  High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.

Authors:  Meliana Riwanto; Ulf Landmesser
Journal:  J Lipid Res       Date:  2013-07-20       Impact factor: 5.922

3.  Oxidative mechanisms and atherothrombotic cardiovascular disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Drug Discov Today Ther Strateg       Date:  2008-03

4.  Proteomic Insight Reveals Elevated Levels of Albumin in Circulating Immune Complexes in Diabetic Plasma.

Authors:  Shweta Bhat; Mashanipalya G Jagadeeshaprasad; Yugendra R Patil; Mahemud L Shaikh; Bhaskaran S Regin; Viswanathan Mohan; Ashok P Giri; Muthuswamy Balasubramanyam; Ramanamurthy Boppana; Mahesh J Kulkarni
Journal:  Mol Cell Proteomics       Date:  2016-04-07       Impact factor: 5.911

Review 5.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

6.  Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome.

Authors:  K G Lagos; T D Filippatos; V Tsimihodimos; I F Gazi; C Rizos; A D Tselepis; D P Mikhailidis; Moses S Elisaf
Journal:  Lipids       Date:  2008-10-28       Impact factor: 1.880

Review 7.  High-density lipoprotein function, dysfunction, and reverse cholesterol transport.

Authors:  Edward A Fisher; Jonathan E Feig; Bernd Hewing; Stanley L Hazen; Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12       Impact factor: 8.311

8.  Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.

Authors:  M Mastorikou; B Mackness; Y Liu; M Mackness
Journal:  Diabet Med       Date:  2008-09       Impact factor: 4.359

Review 9.  HDL as a biomarker, potential therapeutic target, and therapy.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Diabetes       Date:  2009-12       Impact factor: 9.461

10.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.